MDACC Study No:2005-0827 ( NCT No: NCT00411671)
Title:A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients with Advanced Non-small Cell Lung Cancer
Principal Investigator:George Blumenschein
Treatment Agent:BAY 43-9006
Study Status:Terminated
Study Description:The goal of this clinical research study is to evaluate the effectiveness of
Sorafenib (BAY 43-9006) in treating NSCLC. The safety of this treatment will
also be studied, as well as the treatment's effect on different cells in the
body and the participants' overall response.
Hide details for General InformationGeneral Information

Disease Group:Lung
Phase of Study:Phase II
Treatment Agents:BAY 43-9006
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients will return to the clinic every 4 weeks.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:George Blumenschein
Dept:Thoracic and Head and Neck Med
For Clinical Trial Enrollment:713-792-6363
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults